节点文献

谷氨酰胺酶与肿瘤的关系研究进展

Research progress on relationship between glutaminase and tumor

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 黎兵华丁义涛余德才

【Author】 LI Bing-Hua;DING Yi-Tao;YU De-Cai;Department of Hepatobiliary Surgery,Drum Tower Hospital,Medical School of Nanjing University;

【机构】 南京大学医学院附属鼓楼医院肝胆外科

【摘要】 谷氨酰胺依赖是肿瘤细胞的重要代谢特点,谷氨酰胺酶(GLS)催化谷氨酰胺生成谷氨酸的反应,是谷氨酰胺酵解的第一个代谢酶.GLS可分为肾型谷氨酰胺酶(GLS1)和肝型谷氨酰胺酶(GLS2).大多数肿瘤中GLS1高表达,GLS2低表达.GLS1具有"促癌效应",而GLS2具有"抗癌效应".GLS在多种肿瘤的发生发展过程中起重要作用.GLS对肿瘤的诊断、进展及预后评估均具有十分重要的意义.GLS1是肿瘤代谢治疗的潜在靶点,其特异性抑制剂有望成为新型的抗肿瘤代谢药物.本文综述了GLS的基础和临床研究进展,并着重阐述了GLS在临床诊疗中的应用价值.

【Abstract】 Glutamine addiction is one of the metabolic hallmarks of tumor cells. Glutaminase( GLS) catalyzes the first step of glutaminolysis by converting glutamine to glutamate and ammonia.There are two isozymes of GLS, a kidney-type glutaminase( GLS1) and a liver-type glutaminase( GLS2). GLS1 is upregulated in most tumor tissues,while GLS2 is downregulated. GLS1 functions as a tumor-promotor,while GLS2 acts as a tumor-suppressor.GLS plays an important role in the development and progression of multiple tumors. GLS is of much clinical significance in the diagnosis and prognosis evaluation of tumor. GLS1 is a potentially important target for cancer metabolic therapeutics,and the specific inhibitors of GLS1 are promising to become the novel anti-cancer drugs. This review summarized the progress of the basic and clinical research of GLS,and focused on the evaluation of the potential value of glutaminase in the clinical diagnosis and treatment.

【基金】 国家自然科学基金(81372455,81372294);江苏省十三五强卫工程重点人才
  • 【文献出处】 转化医学电子杂志 ,E-Journal of Translational Medicine , 编辑部邮箱 ,2017年12期
  • 【分类号】R730.2
  • 【被引频次】9
  • 【下载频次】763
节点文献中: 

本文链接的文献网络图示:

本文的引文网络